We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




DuPont to Acquire Verdia Subsidiary of Maxygen

By Biotechdaily staff writers
Posted on 09 Jun 2004
To enhance its research and discovery capabilities, DuPont (Wilmington, DE, USA) has agreed to acquire Verdia, Inc. More...
(Redwood City, CA, USA), a subsidiary of Maxygen, Inc. (also in Redwood City).

DuPont plans to purchase the plant sciences company for U.S.$64 million in cash. DuPont will have worldwide, royalty-free rights to use Maxygen's MolecularBreeding directed evolution platform, known as gene shuffling, for agricultural applications across its agriculture and nutrition platform. DuPont plans to retain Verdia's name.

Scientists at Verdia and another DuPont subsidiary, Pioneer Hi-Bred International, unveiled the first agricultural trait developed through gene shuffling in the May 21, 2004, issue of Science. Pioneer currently has this trait, glyphosate resistance, in field tests in corn and expects to have it on the market within the next five to six years. DuPont will be able to tap Verdia technology and expertise to improve plants' health benefits, nutritional value, and taste for the consumer market while also improving processing attributes for food manufacturers.

"Verdia will significantly enhance our gene research and trait discovery capabilities,” said Jim Miller, DuPont vice president, crop genetics research and development. "The technology should allow us to reach research targets up to three years faster and more efficiently.”




Related Links:
DuPont
Maxygen

New
Gold Member
Latex Test
SLE-Latex Test
Serological Pipet Controller
PIPETBOY GENIUS
New
Silver Member
Luteinizing Hormone Test
Luteinizing Hormone (LH) Rapid Test
New
Hepatitis A Rapid Test
Anti-HAV IgM Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: Switching to an experimental drug after liquid biopsy detection of breast cancer recurrence can improve outcomes (Photo courtesy of Shutterstock)

Treatment Switching Guided by Liquid Biopsy Blood Tests Improves Outcomes for Breast Cancer Patients

Standard treatment for patients with advanced estrogen receptor (ER)-positive, HER2-negative breast cancer, a subtype driven by estrogen receptors that fuel tumor growth, often involves aromatase inhibitors,... Read more

Pathology

view channel
Image: A new at-home self-collection device aims to reduce the screening gap for cervical cancer (Photo courtesy of CU School of Medicine)

New At-Home Cervical Cancer Screening Device to Increase Accessibility for Patients

Cervical cancer is typically linked to certain types of human papillomavirus (HPV), which is passed through sexual contact. While many people are infected with HPV, only a small percentage will develop... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.